First Horizon Advisors Inc. Has $130,000 Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

First Horizon Advisors Inc. decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 47.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 307 shares of the company’s stock after selling 274 shares during the quarter. First Horizon Advisors Inc.’s holdings in CRISPR Therapeutics were worth $130,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Fort Sheridan Advisors LLC grew its holdings in CRISPR Therapeutics by 5.8% during the second quarter. Fort Sheridan Advisors LLC now owns 1,829 shares of the company’s stock valued at $296,000 after purchasing an additional 100 shares during the period. Miracle Mile Advisors LLC grew its holdings in CRISPR Therapeutics by 3.2% during the third quarter. Miracle Mile Advisors LLC now owns 3,501 shares of the company’s stock valued at $392,000 after purchasing an additional 110 shares during the period. Bradley Foster & Sargent Inc. CT grew its holdings in CRISPR Therapeutics by 4.9% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 2,581 shares of the company’s stock valued at $418,000 after purchasing an additional 120 shares during the period. HBK Sorce Advisory LLC grew its holdings in CRISPR Therapeutics by 8.3% during the second quarter. HBK Sorce Advisory LLC now owns 1,817 shares of the company’s stock valued at $294,000 after purchasing an additional 140 shares during the period. Finally, Reynders McVeigh Capital Management LLC grew its holdings in CRISPR Therapeutics by 5.9% during the second quarter. Reynders McVeigh Capital Management LLC now owns 2,605 shares of the company’s stock valued at $422,000 after purchasing an additional 145 shares during the period. Institutional investors own 51.94% of the company’s stock.

NASDAQ CRSP opened at $67.77 on Friday. The company has a fifty day simple moving average of $78.24 and a 200 day simple moving average of $105.11. CRISPR Therapeutics AG has a 12-month low of $64.76 and a 12-month high of $220.20. The company has a market cap of $5.19 billion, a P/E ratio of 14.24 and a beta of 2.06.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 3rd. The company reported ($1.67) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.75) by $0.08. CRISPR Therapeutics had a return on equity of 19.19% and a net margin of 45.64%. The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $3.85 million. As a group, sell-side analysts anticipate that CRISPR Therapeutics AG will post 5 EPS for the current fiscal year.

CRSP has been the topic of a number of research reports. Barclays cut their price target on shares of CRISPR Therapeutics from $160.00 to $148.00 and set an “overweight” rating on the stock in a research note on Thursday, November 4th. Chardan Capital reaffirmed a “buy” rating and issued a $171.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, October 13th. SVB Leerink started coverage on shares of CRISPR Therapeutics in a research report on Tuesday, October 19th. They issued an “outperform” rating and a $126.00 price objective on the stock.
Stifel Nicolaus cut their price objective on shares of CRISPR Therapeutics from $139.00 to $101.00 and set a “hold” rating on the stock in a research report on Wednesday, October 13th. Finally, Cowen started coverage on shares of CRISPR Therapeutics in a research report on Monday, December 6th. They issued a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $153.33.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Featured Article: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.